Trial reportAnnals of surgical oncology2026
Conversion Surgery After Induction Therapy for Initially Unresectable Stage III Non-small Cell Lung Cancer: A Proof-of-Concept Trial.
Trial report in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04945928 (Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC
Who cites it
1 citing paper in PubMed.
- Preoperative Frailty Assessment: An Important Component of Preoperative Planning for Lung Cancer Surgery.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundTo prove the concept of conversion surgery after induction therapy in initially unresectable stage III non-small-cell lung cancer (NSCLC), we conducted this single-arm, open label, prospective study. PATIENTS AND
methodsIn this proof-of-concept prospective study, patients with initially unresectable stage III NSCLC who had received induction therapy and evaluated radically resectable were included and underwent surgery. The primary outcome was perioperative morbidity. Bulk-RNA sequencing of baseline and post-treatment samples from patients receiving immunochemotherapy (ICT) as induction therapy was conducted to explore the transcriptomic characteristics of therapeutic response. This study was registered with ClinicalTrials.gov, NCT04945928.
resultsFrom August 2021 to January 2024, 30 patients were enrolled. The R0 resection rate was 93.3% (28/30). Postoperative morbidity was reported in ten patients (33.3%). The rate of major pathologic response and pathological complete response were 66.7% (20/30) and 26.7% (8/30). In a median follow-up time of 17 months (10.2-21.0 months), the rate of 1-year event-free survival and overall survival were 87.5% and 96.7%, respectively. Transcriptomic analysis found a significant association of B cell immunity with MPR after ICT. A gene set derived from the enriched B cell immune-related pathways predicted better survival in patients treated with immunotherapy.
conclusionsConversion surgery after induction therapy was safe and feasible, with encouraging 1-year survival outcomes for selected patients with initially unresectable stage III NSCLC. These foregrounded the role of radical surgery in the treatment strategy in this setting. A B cell immune-related gene set with potential predictive value was also identified within the ICT cohort. CLINICAL TRIAL REGISTRY NUMBER: ClinicalTrials.gov, NCT04945928.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.